Markt geschlossen -
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
0.125 CAD | +13.64% | +13.64% | +92.31% |
Kurzporträt
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Chris Moreau
CEO | Chief Executive Officer | 59 | 01.03.18 |
James Kinley
DFI | Director of Finance/CFO | 45 | 01.12.21 |
Chief Operating Officer | 41 | 01.03.21 | |
Ahmad Khalil
CTO | Chief Tech/Sci/R&D Officer | - | 01.03.21 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Harry Bloomfield
CHM | Chairman | 79 | 08.09.21 |
Chris Moreau
CEO | Chief Executive Officer | 59 | 01.03.18 |
Mark Williams
BRD | Director/Board Member | 52 | 22.09.21 |
James Kinley
DFI | Director of Finance/CFO | 45 | 01.12.21 |
Raj Attariwala
BRD | Director/Board Member | 55 | 26.10.15 |
Howard Gutman
BRD | Director/Board Member | - | 28.02.22 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 21 840 722 | 21 665 319 ( 99,20 %) | 0 | 99,20 % |
Unternehmenskontakt
Algernon Pharmaceuticals, Inc.
601 West Broadway Street Suite 400
V5Z 4C2, Vancouver
+604-398-4175
http://www.algernonpharmaceuticals.comSektor
Quartalsumsätze - Abweichungsrate
% 1. Jan. | Kap. | |
---|---|---|
+92.31% | 2 Mio. | |
+3.91% | 109 Mrd. | |
+10.87% | 105 Mrd. | |
+1.28% | 22.25 Mrd. | |
-13.14% | 22.09 Mrd. | |
-7.05% | 18.68 Mrd. | |
-38.36% | 17.58 Mrd. | |
-10.66% | 16.85 Mrd. | |
+3.75% | 13.76 Mrd. | |
+36.70% | 12.46 Mrd. |
- Börse
- Aktien
- A3DAFG Aktie
- Unternehmen Algernon Pharmaceuticals Inc.